Biohaven Investors Alert: Opportunity to Lead Securities Fraud Lawsuit Over Alleged Misrepresentations

Are you an investor who purchased Biohaven Ltd. (BHVN) securities between March 5, 2021, and November 22, 2022? If so, you may have a crucial opportunity to protect your investments and lead a securities fraud class action lawsuit against the company. A significant legal action is underway, alleging that Biohaven made materially false and misleading statements to its investors, potentially causing substantial financial harm.

The lawsuit centers on serious allegations that Biohaven misled the public regarding critical aspects of its business.

Specifically, it claims the company overstated the efficacy and/or safety profile of its flagship drug, Nurtec ODT (rimegepant). Furthermore, a key contention is that Biohaven failed to disclose vital information concerning the U.S. Food and Drug Administration (FDA)’s likely disapproval of Nurtec ODT for the treatment of generalized anxiety disorder (GAD), citing insufficient clinical data to support such an expansion of its approved uses.

These alleged omissions and misrepresentations are at the heart of the legal challenge.

Investors relied on the information provided by Biohaven to make their investment decisions. If the company indeed presented an inaccurate picture of Nurtec ODT’s performance or its regulatory prospects, particularly concerning a significant market expansion like GAD, then shareholders were operating under false pretenses.

The alleged failure to transparently communicate the FDA’s reservations regarding GAD approval could be considered a severe breach of Biohaven’s duty to its investors.

As a direct result of these purported misleading statements, the lawsuit alleges that Biohaven's public pronouncements were materially false and deceptive at the time they were made.

When the truth eventually emerged, it could have had a detrimental impact on the company's stock value, leading to significant losses for unsuspecting investors who had purchased shares during the specified period. This class action aims to recover those losses and hold the company accountable for its actions.

For those who invested in Biohaven Ltd.

during this critical timeframe, the opportunity to seek recourse is time-sensitive. The deadline to apply to the Court to be appointed as lead plaintiff in this class action lawsuit is September 16, 2025. Becoming a lead plaintiff allows an investor to direct the litigation and play a pivotal role in the recovery process, representing the interests of all affected shareholders.

If you are a Biohaven investor and believe you have been impacted by these alleged securities violations, it is imperative to act promptly.

The Schall Law Firm is actively investigating these claims and encourages affected shareholders to contact them to discuss their legal options. Understanding your rights and taking timely action is crucial to potentially recovering your investment losses and ensuring corporate accountability.